Ther Adv Med Oncol 2022
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Related Questions
Role of capivasertib vs SERD? What factors help you decide?
New answer by Medical Oncologist at VanDeusen Oncology Consulting (March 5, 2024)
This is a question that has been popping up. The Oncology Brothers actually asked this question to Dr. @Hope S. Rugo in their Feb. 22nd podcast. She replied that "Fortuna...